Top Markets
Coin of the day
Andros Pharmaceuticals Co.,Ltd Andros Pharmaceuticals Co.,Ltd

Andros Pharmaceuticals Co.,Ltd

6917
주식 순위 #24789
Andros Pharmaceuticals Co., Ltd. operates as a biopharmaceutical enterprise,... Andros Pharmaceuticals Co., Ltd. operates as a biopharmaceutical enterprise, concentrating on the advancement of novel drug delivery platform technologies. Its development pipeline features APC101, a metered-dose, quick-drying, film-forming spray undergoing Phase IIa clinical investigation for the management of pain linked to post-herpetic neuralgia. Also in development is APC201, an innovative topical anesthetic formulation currently in Phase I/II trials for Osteoarthritis treatment, alongside an siRNA (small interfering RNA) compound functioning as an antisense oligonucleotide and DNA candidate. In the preclinical phase, the company is advancing APC310 and APC501, both intended as anesthetics for intravenous catheter insertion and venipuncture. Another preclinical asset, APC401, is a specialized emulsified solution targeting post-surgical pain relief. Beyond its developmental programs, Andros Pharmaceuticals also provides LALP cream for dermal analgesic use, iMinos solution for treating Alopecia Androgenetica, and T4 endonuclease V. Established in 2008, the firm maintains its headquarters in Zhubei, Taiwan.
주가
$1.03
시가총액
$56.61M
변동 (1일)
0.00%
변동 (1년)
80.30%
국가
TW
거래 Andros Pharmaceuticals Co.,Ltd (6917)

카테고리

Andros Pharmaceuticals Co.,Ltd (6917)의 EPS
2026 기준 EPS TTM: 0
Andros Pharmaceuticals Co.,Ltd의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Andros Pharmaceuticals Co.,Ltd의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
$-7.98 -
US
- -
CH